COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature
Elif Aksoy, Turgut Öztutgan
Abstract
Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weakness. This is one of the early cases of COVID-19 reported in association with myasthenia gravis. Here, we highlight the prognosis, discuss the pathophysiological mechanisms, and prompt the consideration of convalescent plasma therapy in myasthenia gravis patients with concomitant COVID-19.
Topics & Concepts
Myasthenia gravisMedicineCoronavirus disease 2019 (COVID-19)ConcomitantPresentation (obstetrics)WeaknessRespiratory failureRespiratory system2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineInternal medicineSurgeryPathologyDiseaseOutbreakInfectious disease (medical specialty)Myasthenia Gravis and ThymomaLong-Term Effects of COVID-19Parkinson's Disease and Spinal Disorders